Navigation Links
Isotechnika's independent data monitoring committee conducts review,,,of phase 2b kidney transplant trial

the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. %SEDAR: 00010508E

-30-

/For further information: Dr. Randall Yatscoff, President & COO, Isotechnika Inc., Phone: (780) 487-1600 Ext. 246, Fax: (780) 484-4105, Email: ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director, Corporate Communications, Isotechnika Inc., Phone: (780) 487-1600 Ext. 243, Fax: (780) 484-4105, E-mail:sgillis-paulgaard@isotechnika.com/


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
6. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
7. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
8. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
9. Ad hoc: Interim report about clinical trial of BF-200 ALA in actinic keratosis
10. Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404
Post Your Comments:
(Date:1/6/2009)...ng a healthy immune system , , PURCHASE, N.Y., ...in Nutrition and Cancer (60(5), 643-651) by rese...an has shown that AHCC (Active Hexose Correlated C...e number of dendritic cells (DCs). DCs are a key p...g foreign substances to other immune system cells....
(Date:1/6/2009)... -- Pacira Pharmaceuticals, Inc., an,acute care s...hat enrollment,has been completed in two pivotal ...d efficacy of a single intraoperative administrati... postoperative analgesia. , Results from th...rthroplasty (TKA) are expected to provide the prim...
(Date:1/3/2009)...., Jan. 2 Magnetic reso...ing an increasing number of clinical benefits when...an article in the January 2009 issue of the Journa...( http://www.jaaos.org/ ). It is predicted that o...evelopments will allow MRI to provide even more us...
(Date:12/27/2008)..., offers to ease cloning costs for Clonaid clients...RNewswire-USNewswire/ -- Six years to the day afte...r. Brigitte Boisselier, head of the company that l...s cloned by her company are growing up healthy and... privacy. , , "We,ve helped almost 100 families...
Breaking Medicine Technology:Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3'We're Ready to Prove It!' 2Rosalind Franklin University of Medicine and Science First in Illinois to Equip Students With Computerized Diagnosis System 31928 1Rosalind Franklin University of Medicine and Science First in Illinois to Equip Students With Computerized Diagnosis System 31928 2Make a Mental Wellness New Years Resolution 3A How to Reduce Stress and Maintain Mental Health and Wellness in the Face of Economic Challenges 31926 1Make a Mental Wellness New Years Resolution 3A How to Reduce Stress and Maintain Mental Health and Wellness in the Face of Economic Challenges 31926 2Make a Mental Wellness New Years Resolution 3A How to Reduce Stress and Maintain Mental Health and Wellness in the Face of Economic Challenges 31926 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA Based Diagnostic Test 3B Will Host Teleconference to Discuss Launch of Future 3613 1Rosetta Genomics Announces Commercial Availability of its First MicroRNA Based Diagnostic Test 3B Will Host Teleconference to Discuss Launch of Future 3613 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA Based Diagnostic Test 3B Will Host Teleconference to Discuss Launch of Future 3613 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA Based Diagnostic Test 3B Will Host Teleconference to Discuss Launch of Future 3613 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA Based Diagnostic Test 3B Will Host Teleconference to Discuss Launch of Future 3613 5Danialle Karmanos Work It Out Names Tracey Secco as Director of Operations 31923 1Danialle Karmanos Work It Out Names Tracey Secco as Director of Operations 31923 2
(Date:1/8/2009)...ire-FirstCall/ - Med-Emerg International Inc. (OTC...viders of health services, is pleased to announce ...previously announced plan of arrangement (the "Arr... special meeting of MedEmerg,s shareholders held i...t at the meeting were in favour of the Arrangement...
(Date:1/8/2009)... Today, the National Hos...everal national leadership organizations issued a ...spice care and protection of the Medicare Hospice ...aring this unified message about end-of-life care ...tive Medicine, Hospice and Palliative Nurses Assoc...
(Date:1/8/2009)...er Tom Torlakson Introduces AB 89 , , SACRAMENT...ay, Lung Cancer Alliance-California (LCA-CA), hail...h District) for his continued leadership in introd...r research. For the third consecutive year, legis...ng considered in the California Legislature. , ...
(Date:1/8/2009)...holesterol more effectively than Zocor , ...ly a year of review, U.S. health officials said Th...e controversial cholesterol-lowering drug Vytorin....here was no significant difference in carotid arte...atients taking the drug Zocor. , But, the agenc...
Breaking Medicine News(10 mins):Health News:Shareholders of Med-Emerg International Inc. approve plan of arrangement with AIM Health Group Inc. 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2
...ster Kapil Sibal Friday unveiled two test kits tha...just an hour.// The kits, developed by the Intern...nology (ICGEB) here, use specially designed synthe...tely detect the diseases. Sibal said both kits us...
...blished the prevailing trend among kids of today, ...ick fix snack options.// Researchers from univers...urvey which revealed the unwholesome truth about e...s and kids must know the pitfalls of unhealthy eat...
...es the risk of death from prostate cancer, even th...ill be diagnosed with the disease.// Published i...the American Cancer Society, the study reveals tha...ight gain in adulthood correlated strongly with in...
...indfulness’ is now being taught to Queensland wome...based technique provides a// solution for women wh...ing taught to help them understand and deal with t... Unlike many therapies for eating disorders, there...
Other Medicine News:Health News:Excess Weight and Adult Weight Gain Increase Risk of Prostate Cancer Death 2
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 2.7V vacuum lamp source.
Designed for instrumentation under magnification. Both lens and speculum can be swivelled. Open construction to allow access and examination under magnification and illumination.
Pocket-sized instrument with direct illumination. Avaliable in black, green or blue.
Pocket-sized instrument, powered by two AA-sized alkaline batteries. Built-in throat illuminator, rectangular viewing lens for instrumentation under magnification.
Medicine Products: